文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

脓毒性休克患者的辅助糖皮质激素治疗

Adjunctive Glucocorticoid Therapy in Patients with Septic Shock.
PubMed 文献 · N Engl J Med · 2018-01-19
一句话结论在机械通气的脓毒性休克患者中,持续输注氢化可的松并未降低90天死亡率(27.9% vs 28.8%,OR 0.95)。

ADRENAL试验将3800例接受机械通气的脓毒性休克患者随机分配至氢化可的松200 mg/日持续输注组或安慰剂组,疗程7天或直至死亡或ICU出院。90天时氢化可的松组死亡率27.9%,安慰剂组28.8%(OR 0.95;95%CI 0.82至1.10;P=0.50),六个预设亚组效果相似。氢化可的松组休克缓解更快(中位3天 vs 4天;HR 1.32;95%CI 1.23至1.41;P<0.001),初始机械通气时间更短(中位6天 vs 7天;HR 1.13;95%CI 1.05至1.22;P<0.001),但计入复发通气后无显著差异;输血更少(37.0% vs 41.7%;OR 0.82;95%CI 0.72至0.94;P=0.004)。结论:持续输注氢化可的松未降低90天死亡率。

要点

  • 机械通气的脓毒性休克患者中,氢化可的松200 mg/日持续输注未降低90天死亡率(27.9% vs 28.8%;OR 0.95;95%CI 0.82至1.10;P=0.50)。
  • 氢化可的松组休克缓解更快:中位3天(IQR 2至5)vs 安慰剂组4天(IQR 2至9);HR 1.32;95%CI 1.23至1.41;P<0.001。
  • 氢化可的松组初始机械通气时间更短:中位6天(IQR 3至18)vs 7天(IQR 3至24);HR 1.13;95%CI 1.05至1.22;P<0.001;但计入复发通气后无显著差异。
  • 氢化可的松组输血更少:37.0% vs 41.7%;OR 0.82;95%CI 0.72至0.94;P=0.004。
  • 28天死亡率、休克复发率、存活且出ICU天数、存活且出院天数、复发机械通气、肾脏替代治疗率、新发菌血症或真菌血症发生率组间无显著差异。

适用人群与场景

  • 接受机械通气的脓毒性休克患者。

处置流程与药物剂量

  • 氢化可的松200 mg/日持续输注,疗程7天或直至死亡或ICU出院,以先发生者为准(研究方案)。

研究设计与关键结果

  • 多中心随机对照试验,2013年3月至2017年4月共随机3800例,3658例(氢化可的松组1832例,安慰剂组1826例)获得主要结局数据。
  • 90天死亡率:氢化可的松组27.9%(511例)vs 安慰剂组28.8%(526例);OR 0.95;95%CI 0.82至1.10;P=0.50。
  • 休克缓解:氢化可的松组中位3天(IQR 2至5)vs 安慰剂组4天(IQR 2至9);HR 1.32;95%CI 1.23至1.41;P<0.001。
  • 初始机械通气持续时间:氢化可的松组中位6天(IQR 3至18)vs 安慰剂组7天(IQR 3至24);HR 1.13;95%CI 1.05至1.22;P<0.001;计入复发通气后无显著差异。
  • 输血:氢化可的松组37.0% vs 安慰剂组41.7%;OR 0.82;95%CI 0.72至0.94;P=0.004。
  • 28天死亡率、休克复发率、存活且出ICU天数、存活且出院天数、复发机械通气、肾脏替代治疗率、新发菌血症或真菌血症发生率组间无显著差异。
  • 六个预设亚组中试验方案效果相似。

证据类型、等级与局限

  • 证据类型:多中心随机对照试验(ADRENAL,NCT01448109)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在机械通气的脓毒性休克患者中,持续输注氢化可的松未降低90天死亡率,但可更快缓解休克、缩短初始机械通气时间并减少输血。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Whether hydrocortisone reduces mortality among patients with septic shock is unclear.

METHODS: We randomly assigned patients with septic shock who were undergoing mechanical ventilation to receive hydrocortisone (at a dose of 200 mg per day) or placebo for 7 days or until death or discharge from the intensive care unit (ICU), whichever came first. The primary outcome was death from any cause at 90 days.

RESULTS: From March 2013 through April 2017, a total of 3800 patients underwent randomization. Status with respect to the primary outcome was ascertained in 3658 patients (1832 of whom had been assigned to the hydrocortisone group and 1826 to the placebo group). At 90 days, 511 patients (27.9%) in the hydrocortisone group and 526 (28.8%) in the placebo group had died (odds ratio, 0.95; 95% confidence interval [CI], 0.82 to 1.10; P=0.50). The effect of the trial regimen was similar in six prespecified subgroups. Patients who had been assigned to receive hydrocortisone had faster resolution of shock than those assigned to the placebo group (median duration, 3 days [interquartile range, 2 to 5] vs. 4 days [interquartile range, 2 to 9]; hazard ratio, 1.32; 95% CI, 1.23 to 1.41; P<0.001). Patients in the hydrocortisone group had a shorter duration of the initial episode of mechanical ventilation than those in the placebo group (median, 6 days [interquartile range, 3 to 18] vs. 7 days [interquartile range, 3 to 24]; hazard ratio, 1.13; 95% CI, 1.05 to 1.22; P<0.001), but taking into account episodes of recurrence of ventilation, there were no significant differences in the number of days alive and free from mechanical ventilation. Fewer patients in the hydrocortisone group than in the placebo group received a blood transfusion (37.0% vs. 41.7%; odds ratio, 0.82; 95% CI, 0.72 to 0.94; P=0.004). There were no significant between-group differences with respect to mortality at 28 days, the rate of recurrence of shock, the number of days alive and out of the ICU, the number of days alive and out of the hospital, the recurrence of mechanical ventilation, the rate of renal-replacement therapy, and the incidence of new-onset bacteremia or fungemia.

CONCLUSIONS: Among patients with septic shock undergoing mechanical ventilation, a continuous infusion of hydrocortisone did not result in lower 90-day mortality than placebo. (Funded by the National Health and Medical Research Council of Australia and others; ADRENAL ClinicalTrials.gov number, NCT01448109 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Venkatesh B, Finfer S, Cohen J, et al. Adjunctive Glucocorticoid Therapy in Patients with Septic Shock. N Engl J Med. 2018. PMID: 29347874. doi:10.1056/NEJMoa1705835

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。